Enterix

Enterix Inc. is a biotechnology company based in the U.S. and a wholly owned subsidiary of Quest Diagnostics. Founded in 1997, Enterix specializes in developing, manufacturing, marketing, and distributing advanced colorectal cancer screening products. Their primary focus is on fecal immunochemical tests (FIT) that detect lower gastrointestinal bleeding disorders, which may indicate colorectal cancer or other gastrointestinal conditions. The company's flagship product line includes the InSure® FIT tests, such as InSure ONE™ and ColoVantage® Home. These tests simplify the screening process by using only a water sample from a single bowel movement, eliminating the need for stool sample handling. They are low-cost, effective, and do not require refrigeration or dietary changes. Enterix's tests are CLIA-waived and FDA-registered, making them suitable for point-of-care settings to enhance patient compliance with annual screening recommendations. Enterix operates FDA-registered and TGA-licensed manufacturing facilities in the U.S. and Australia, and it is dedicated to providing reliable screening tools for early detection and improved treatment decisions in colorectal disease. The company supports healthcare professionals and institutions with a dedicated customer care team and online resources.

• Employees 38
• Founded 2006
• Annual Revenue $10000000